

Press release

EQ^L PHARMA

Lund, September 17th, 2020

EQ^L Pharma AB (publ)

556713-3425

Approval of Phenoxymethylpenicillin EQ^L

The pharmaceutical Phenoxymethylpenicillin EQ^L, granules for oral suspension 50mg/ml, 100mg/ml and oral solution 250mg/ml, have been approved for sale by the Danish Medicines Agency. A further approval in Sweden is expected soon.

Phenoxymethylpenicillin EQ^L is a prescription antibiotic used to treat common bacterial infections such as ear infections and Lyme disease in children and adults.

Phenoxymethylpenicillin EQ^L contains phenoxymethylpenicillin, a substance which has been registered as granules for oral solution/suspension in Sweden since 1978 under the trademark Kåvepenin®. The market for phenoxymethylpenicillin granules for oral solution/suspension is estimated to approx. SEK 20 million in total annual sales in Sweden and Denmark.

The product is expected to be launched during EQ^L Pharma's third financial quarter, 2021/22.

For further information, please contact:

Christer Fåhraeus

CEO, EQ^L Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: christer.fahraeus@eqlpharma.com

Website: www.eqlpharma.com

EQ^L Pharma AB (publ) in short

EQ^L Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 18 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2020 and beyond. The business is currently entirely focused on prescription drugs. EQ^L Pharma AB conducts its operations in Lund, employs 9 people and is listed on the Spotlight Stock Market. EQ^L Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.